source
- Novartis and Novo Nordisk see back-to-back cardiovascular trial failures, raising doubts for the fieldNovartis announced that its experimental heart‑protective therapy, pelacarsen, did not meet its primary endpoints in a seven‑year study designed to cut heart attacks and strokes by lowering lipopro…
- GSK’s risvutatug rezetecan shows 18.5-month median overall survival in phase 3 SCLC trialGSK, together with Chinese partner Hansoh Pharma, reported results of its antibody‑drug conjugate risvutatug rezetecan (ris‑rez) in a phase 3 trial for relapsed small‑cell lung cancer. The study e…